Arrayo

A recent INFORMS article by Swechcha G. highlights how agentic AI is transforming BI reporting by automating analysis, surfacing insights proactively, and adapting to evolving business needs. The piece shows how shifting from static dashboards to autonomous, real-time intelligence can significantly accelerate decision-making and reduce blind spots. If you're exploring how agentic AI could reshape decision-making in your organization, this article is a great place to start. https://lnkd.in/ebHx85TF

Insight generation isn’t enough — as Laxmi Vanam aptly highlights, real transformation comes from insight orchestration. It’s a challenge many of our clients in Financial Services and Life Sciences face. This article captures that shift perfectly. https://lnkd.in/euhwwBFs

Check out this great interview with BMS CDTO Greg Meyers on how AI is transforming biopharma – from accelerating R&D to shaping new digital capabilities. His advice? “A demo is worth a thousand slides.” Insightful listen on innovation, experimentation, and the future of AI in life sciences. https://lnkd.in/eFbRfNVB

Looking for insights on what’s shaping the future of biopharma? This recent article from MassBio highlights three key forces redefining the industry: policy and pricing pressures, fierce global competition, and the transformative power of AI. AI’s potential to generate billions in cost savings and boost innovation is especially compelling. For anyone interested in how biopharma will navigate uncertainty and seize new opportunities, this is a must-read. #AI #Biopharmas https://lnkd.in/dwBKeTXM

AI Boom or Bubble in Life Sciences?https://lnkd.in/g6B-jfse The pharma industry is riding the AI wave - from protein folding to trial optimization - but are we building sustainable value or inflating another tech bubble? This PharmaVoice piece explores how the sector’s long R&D timelines, regulatory rigor, and measurable ROI could insulate it from the broader AI hype cycle. Yet, as investment pours in and expectations soar, the line between revolution and overreach is blurring fast.Worth a read for anyone thinking about where real innovation ends and speculation begins. #AI #LifeSciences #DrugDiscovery #Pharma #Innovation

Spreadsheets are the original low-code platform — and their persistence tells us something important. BizTech and Dave Nyczepir recently noted that 70% of CFOs still rely on spreadsheets for core planning and reporting. The issue isn’t just data risk or broken formulas — it’s that we haven’t yet given business users a better, governed alternative. The rise of citizen-led automation is changing that. It channels the same creativity that made spreadsheets so powerful — but moves it onto platforms that are secure, auditable, and connected. Instead of “shadow IT,” we get empowered innovation with oversight. The future of finance and operations won’t be about banning spreadsheets — it’ll be about evolving them into structured, governed automation ecosystems. #FinanceTransformation #CitizenLedAutomation #DataGovernance #Data #Automation https://lnkd.in/etbiCm3B

Check out this post from Michael Gibney which elaborates on how artificial intelligence is poised to transform drug discovery and development. Within the next five years, which area(s) of R&D do you think will be most impacted by the application of AI? https://lnkd.in/enRiKDZp

Read about the 2025 Nobel Prize in Physiology or Medicine, that celebrates groundbreaking discoveries on how our immune system is precisely regulated to protect us from infections while preventing it from attacking our own body. Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi have identified key mechanisms of peripheral immune tolerance and regulatory T cells. Their work has opened new avenues for treating autoimmune diseases, cancer, and improving organ transplant outcomes - demonstrating the power of fundamental science to transform medicine. #Medicine #Lifesciences #Nobelprize https://lnkd.in/euitkCRy

Bristol Myers, Takeda, AbbVie & J&J are pooling structural biology data (protein + small molecule) to train OpenFold3 — all via federated AI so nobody loses control of their IP. Why this matters:  • Better models = smarter drug design & fewer dead ends  • Federated frameworks = trust + scale  • Collaborative approach could redefine how pharma does AI Work in drug discovery, AI, or biotech? Would love to hear your take: Is federated AI the key to unlocking real innovation in life sciences without giving up data ownership? https://lnkd.in/g8QESQiJ #LifeSciences #AI #DrugDiscovery #FederatedLearning #OpenFold3 #HealthTech

AI in finance isn’t about the tools — it’s about alignment, governance, and talent. This Harvard Business Review article makes the case that real success comes from strategy and collaboration, not just new models. Essential reading for leaders ready to move from pilots to lasting impact. https://lnkd.in/grnqhq4e